177 related articles for article (PubMed ID: 3698769)
1. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility.
Alphin RS; Proakis AG; Leonard CA; Smith WL; Dannenburg WN; Kinnier WJ; Johnson DN; Sancilio LF; Ward JW
Dig Dis Sci; 1986 May; 31(5):524-9. PubMed ID: 3698769
[TBL] [Abstract][Full Text] [Related]
2. The action of dazopride to enhance gastric emptying and block emesis.
Costall B; Domeney AM; Gunning SJ; Kelly ME; Naylor RJ; Nohria V; Owera-Atepo JB; Simpson KM; Tan CC; Tattersall D
Neuropharmacology; 1987 Jul; 26(7A):669-77. PubMed ID: 3114664
[TBL] [Abstract][Full Text] [Related]
3. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs.
Gullikson GW; Loeffler RF; Viriña MA
J Pharmacol Exp Ther; 1991 Jul; 258(1):103-10. PubMed ID: 2072288
[TBL] [Abstract][Full Text] [Related]
4. BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.
Gylys JA; Wright RN; Nicolosi WD; Buyniski JP; Crenshaw RR
J Pharmacol Exp Ther; 1988 Mar; 244(3):830-7. PubMed ID: 2978041
[TBL] [Abstract][Full Text] [Related]
5. Effects of cholinoceptor and 5-hydroxytryptamine3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis.
Qin XY; Pilot MA; Thompson H; Scott M
Br J Pharmacol; 1993 Jan; 108(1):44-9. PubMed ID: 8094027
[TBL] [Abstract][Full Text] [Related]
6. Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.
Grant SC; Kris MG; Gralla RJ; Clark RA; Tyson LB
Cancer Chemother Pharmacol; 1993; 31(6):442-4. PubMed ID: 8453682
[TBL] [Abstract][Full Text] [Related]
7. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.
Costall B; Domeney AM; Naylor RJ; Tattersall FD
Neuropharmacology; 1987 Sep; 26(9):1321-6. PubMed ID: 2890117
[TBL] [Abstract][Full Text] [Related]
8. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
[TBL] [Abstract][Full Text] [Related]
9. Substituted benzamides with conformationally restricted side chains. 1. Quinolizidine derivatives as selective gastric prokinetic agents.
Hadley MS; King FD; McRitchie B; Turner DH; Watts EA
J Med Chem; 1985 Dec; 28(12):1843-7. PubMed ID: 4068007
[TBL] [Abstract][Full Text] [Related]
10. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties.
Yoshida N; Omoya H; Oka M; Furukawa K; Ito T; Karasawa T
Arch Int Pharmacodyn Ther; 1989; 300():51-67. PubMed ID: 2533479
[TBL] [Abstract][Full Text] [Related]
11. Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists.
King FD; Hadley MS; McClelland CM
J Med Chem; 1988 Sep; 31(9):1708-12. PubMed ID: 2900897
[TBL] [Abstract][Full Text] [Related]
12. General pharmacology of the four gastrointestinal motility stimulants bethanechol, metoclopramide, trimebutine, and cisapride.
Megens AA; Awouters FH; Niemegeers CJ
Arzneimittelforschung; 1991 Jun; 41(6):631-4. PubMed ID: 1930352
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.
Costall B; Domeney AM; Naylor RJ; Tattersall FD
Neuropharmacology; 1986 Aug; 25(8):959-61. PubMed ID: 3774121
[TBL] [Abstract][Full Text] [Related]
14. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs.
Fukui H; Yamamoto M; Sato S
Jpn J Pharmacol; 1992 Jun; 59(2):221-6. PubMed ID: 1434118
[TBL] [Abstract][Full Text] [Related]
15. Effects of KW-5338 (domperidone) on gastric motility.
Shuto K; Shiozaki S; Kojima T; Tanaka M
J Pharmacobiodyn; 1980 Dec; 3(12):715-9. PubMed ID: 7277187
[TBL] [Abstract][Full Text] [Related]
16. Metoclopramide and sulpiride as selective blocking agents of pre- and postsynaptic dopamine receptors.
Alander T; Andén NE; Grabowska-Andén M
Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun; 312(2):145-50. PubMed ID: 7402361
[TBL] [Abstract][Full Text] [Related]
17. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs.
Iwanaga Y; Miyashita N; Saito T; Morikawa K; Itoh Z
Jpn J Pharmacol; 1996 Jun; 71(2):129-37. PubMed ID: 8835639
[TBL] [Abstract][Full Text] [Related]
18. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
19. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
Kenward H; Elliott J; Lee T; Pelligand L
BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of cisplatin induced emesis in the dog.
Gylys JA; Doran KM; Buyniski JP
Res Commun Chem Pathol Pharmacol; 1979 Jan; 23(1):61-8. PubMed ID: 441517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
